Target Name: OPRM1
NCBI ID: G4988
Review Report on OPRM1 Target / Biomarker Content of Review Report on OPRM1 Target / Biomarker
OPRM1
Other Name(s): Opioid receptor mu 1, transcript variant MOR-1B4 | Opioid receptor mu 1, transcript variant MOR-1A | hMOP | OPRM1 variant MOR-1G2 | Opioid receptor mu 1, transcript variant MOR-1 | OPRM_HUMAN | OPRMI | Opioid receptor mu 1, transcript variant MOR-1B2 | MOR-1O | MOR-1H | OPRM1 variant MOR-1 | MOR-1B1 | Opioid receptor, mu 1, transcript variant MOR-1S | MOR1B5 | Opioid receptor mu 1, transcript variant MOR-1CA | Mu-type opioid receptor (isoform MOR-1B4) | OPRM1 variant MOR-1i | Mu-type opioid receptor (isoform MOR-1O) | MOR-1i | Opioid receptor mu 1, transcript variant MOR-1A2 | OPRM1 variant MOR-1X | MOP | mu-type opioid receptor (isoform MOR-1O) | Mu-type opioid receptor (isoform MOR-1H) | OPRM1 variant MOR-1O | Mu-type opioid receptor (isoform MOR-1A2) | Mu-type opioid receptor (isoform MOR-1G2) | OPRM1 variant MOR-1A2 | MOR-1 | Opioid receptor mu 1, transcript variant MOR-1G1 | Opioid receptor mu 1, transcript variant MOR-1G2 | OPRM1 variant MOR-1B5 | Mu-type opioid receptor (isoform MOR-1B1) | OPRM1 variant MOR-1A | OPRM | MOR-1A | Mu opioid receptor hMOR-1a | OPRM1 variant MOR-1B2 | MOR-1C | M-OR-1 | Mu opiate receptor | Opioid receptor mu 1, transcript variant MOR-1X | OPRM1 variant MOR-1K1 | OPRM1 variant MOR-1G1 | MOR-1K | Opioid receptor mu 1, transcript variant MOR-1B3 | OPRM1 variant MOR-1CA | opioid receptor mu 1 | MOR-1G2 | mu Opiate receptor | mu-type opioid receptor (isoform MOR-1G2) | MOR1A | Opioid receptor mu 1, transcript variant MOR-1O | OPRM1 variant MOR-1B3 | Mu-type opioid receptor (isoform MOR-1G1) | mu opioid receptor hMOR-1a | mu opiate receptor | Mu-type opioid receptor (isoform MOR-1A) | OPRM1 variant MOR-1B1 | Opioid receptor mu 1, transcript variant MOR-1B5 | MOR1B1 | Mu-type opioid receptor (isoform MOR-1i) | OPRM1 variant MOR-1B4 | Opioid receptor mu 1, transcript variant MOR-1B1 | OPRM1 variant MOR-1S | MOR | Opioid receptor, mu 1, transcript variant MOR-1i | Mu-type opioid receptor (isoform MOR-1) | MOR-1B5 | Mu-type opioid receptor (isoform MOR-1B3) | Mu-type opioid receptor (isoform MOR-1B5) | Mu-type opioid receptor (isoform MOR-1B2) | LMOR | mu-Type opioid receptor | Mu-type opioid receptor (isoform MOR-1X) | Opioid receptor mu 1, transcript variant MOR-1K1 | Mu opioid receptor | Mu-type opioid receptor (isoform MOR-1S) | Mu-type opioid receptor | MOR-1G1 | MOR1-K1 | MOR1

Overview of OPRM1 and Its Potential as A Drug Target and Biomarker

OPRM1 (Opioid receptor mu 1, transcript variant MOR-1B4) is a non-c coding RNA (ncRNA) that has been shown to play a critical role in the regulation of pain and inflammation. Despite its importance, little is known about OPRM1 and its potential as a drug target or biomarker. In this article, we will explore OPRM1 and its potential as a drug target and biomarker, as well as its current research status and future prospects.

OPTM1, also known as OPRM1, is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is a splicing variant of OPRM1, which is a gene that encodes the protein opioid receptor mu 1 (ORL1). ORL1 is a G protein-coupled receptor (GPCR) that is involved in the regulation of pain and inflammation. Themu protein family, which includes ORL1, is a subfamily of GPCRs that are involved in the regulation of pain and inflammation.

OPTM1 is expressed in various tissues and cells throughout the body, including the brain, spinal cord, and peripheral tissues. It has been shown to be involved in the regulation of pain perception, neuroinflammation, and inflammation. For example, OPRM1 has been shown to be involved in the regulation of pain sensitivity in response to peripheral tissue injury or inflammation. It has also been shown to be involved in the regulation of neuroinflammation, as it has been shown to be involved in the recruitment of immune cells to the site of inflammation.

OPTM1 is a potential drug target due to its involvement in the regulation of pain and inflammation. Its function as a drug target could be the development of pain and inflammation therapies. For example, OPRM1 could be targeted with small molecules or antibodies to reduce pain sensitivity or the production of neuroinflammation. Additionally, OPRM1 could also be used as a biomarker to predict the effectiveness of pain and inflammation therapies.

OPTM1 is also a potential biomarker for various diseases, including pain disorders, neuroinflammatory diseases, and cancer. Its involvement in the regulation of pain and inflammation makes it a promising biomarker for these diseases. For example, OPRM1 has been shown to be involved in the regulation of pain sensitivity in cancer, which could be used as a biomarker for cancer pain. Additionally, OPRM1 has also been shown to be involved in the regulation of neuroinflammation, which could be used as a biomarker for neuroinflammatory diseases.

OPTM1 is a small RNA molecule that can be expressed and translated into proteins in various cell types. Its function as a protein is not well understood, but it is thought to be involved in the regulation of various cellular processes, including cell survival, cell proliferation , and protein synthesis.

In conclusion, OPRM1 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of pain and inflammation. Its potential as a drug target and biomarker make it an attractive target for research in the development of pain and inflammation therapies. Further research is needed to fully understand its function as a protein and its potential as a drug and biomarker.

Protein Name: Opioid Receptor Mu 1

Functions: Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:10529478, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:10529478, PubMed:9689128, PubMed:10836142, PubMed:19300905). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)

The "OPRM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OPRM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1